In this issue of JAMA, Fan et al 1 review the treatment of acute respiratory distress syndrome (ARDS), focusing on recent randomized clinical trials (RCTs). Most of these RCTs failed to show that the interventions that were tested offered significant benefit. These predominantly negative results may prompt the question of whether other rational and more-effective ways are available to increase knowledge and improve treatment of a syndrome that is common, deadly, and arguably emblematic of modern intensive care. Although many of these trials were admirably executed, their failure to demonstrate benefit may often have been due to uncertainties regarding enrollment criteria and imprecise deployment of the interventions that were being tested.Critical care physicians and others have learned from laboratory experimentation and clinical observation that the pathobiology of ARDS changes rapidly over hours and days, is highly variable from patient to patient, and is influenced by important co-factors. Thus, wise selection of treatment requires consideration of the timing and intensity of any proposed intervention. Furthermore, patients with ARDS often have multiple concomitant medically and surgically related problems, which can confound interpretation of the effects of ARDS-specific interventions. Perhaps, in rethinking the approach to ARDS, it is valuable to revisit the often-missed link between diagnosis and treatment, with more in-depth understanding of the underlying mechanisms responsible for the clinical manifestations of the syndrome.